• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference on March 8 Register Now

    3/7/23 7:00:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INM alert in real time by email

    MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    March 8, 2023, Schedule: (Eastern Time)

    For updates, follow us on Twitter

    9:15

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    9:40 – 10:10

    Visium Technologies (OTC:VISM)

    Mark Lucky, CEO

    10:15 - 10:45

    Nextech AR Solutions (OTCQX:NEXCF) (CSE:NTAR)

    Evan Gappelberg, CEO

    10:50 - 11:20

    HueDx – A Technology Platform

    Mark Wingertzahn, CEO

    Brianna Wronko-Stevens

    Founder & CSO, Sam Parks, CTO

    11:25 – 11:55

    CoTec (TSXV:CTH)

    Julian Treger, President / CEO

    12:00 – 12:30

    InMed Pharmaceuticals (NASDAQ:INM)

    Eric Adams, CEO

    12:35 – 1:05

    SinglePoint, Inc. (OTCQB:SING)

    Wil Ralston, CEO

    1:10 – 1:20

    Regen BioPharma, Inc., (OTC:RGBP) and (OTC:RGBPP)

    David Koos, President / CEO

    Harry M. Lander, Ph.D. Senior Scientific Consultant

    1:25 – 1:55

    China Dongsheng International Inc. (OTC Markets: CDSG)

    Craig Steven Alford, CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $INM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INM

    DatePrice TargetRatingAnalyst
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $INM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for December 11th

    NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please Schedule 1x1 Meetings Here "We are excited to host our Life Sciences Virtual Investor Forum on December 11th," said Jason Paltrowitz,

    12/9/25 8:35:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

    NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O

    9/18/25 8:35:00 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

    Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed's CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. DATE: September 18th    TIME: 2:00 PM ET LINK:  REGISTER HEREAvailable for 1x1 meetings: Sept

    9/16/25 1:39:13 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    SEC Filings

    View All

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 8:51:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by InMed Pharmaceuticals Inc.

    10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 5:04:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by InMed Pharmaceuticals Inc.

    SCHEDULE 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    1/20/26 2:25:27 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    11/29/21 6:20:24 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on InMed Pharmaceuticals with a new price target

    Roth Capital reiterated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $11.50 from $12.00 previously

    2/16/21 11:09:34 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sr VP & General Manager Johnson Shane Aaron

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:54 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lemerond Nicole

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:35 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Klompas Neil A

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:16 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/22/24 1:38:46 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/21/24 2:58:17 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/14/24 4:36:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

    SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/12/24 1:44:16 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc. (Amendment)

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    2/14/24 2:28:27 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Leadership Updates

    Live Leadership Updates

    View All

    InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

    VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid

    12/12/22 6:47:35 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Announces Changes to its Board of Directors

    VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets.  Throughout her career, Ms. Lemerond has worked with public

    8/9/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Announces Appointment of Chief Operating Officer

    VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa

    7/18/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INM
    Financials

    Live finance-specific insights

    View All

    InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

    VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay available for 12 months) To access the call by phone, please go to the registration link, and you will be provided w

    9/19/22 6:00:00 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

    Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the development, manufacturing and commercialization of rare cannabinoids,

    2/14/22 7:34:02 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

    VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 8645175Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv (*Webcast replay available

    2/10/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care